Earnings Outlook For McCormick & Co

McCormick & Co (NYSE:MKC) is set to give its latest quarterly earnings report on Tuesday, 2023-03-28. Here’s what…

McCormick & Co (NYSE:MKC) is set to give its latest quarterly earnings report on Tuesday, 2023-03-28. Here’s what investors need to know before the announcement.

Analysts estimate that McCormick & Co will report an earnings per share (EPS) of $0.52.

McCormick & Co bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company missed EPS by $0.13, which was followed by a 1.33% increase in the share price the next day.

Here’s a look at McCormick & Co’s past performance and the resulting price change:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate 0.86 0.94 0.65 0.62
EPS Actual 0.73 0.69 0.48 0.63
Price Change % 1.33% 1.9% -2.45% 0.4%

eps graph

Stock Performance

Shares of McCormick & Co were trading at $72.87 as of March 24. Over the last 52-week period, shares are down 23.89%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

To track all earnings releases for McCormick & Co visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue And Provides Corporate Updates; Sees Q4 Revenue $69M-$71M Vs $68.27M Est.; FY23 Revenue $178M-$180M Vs $185.4M Est.; LIVMARLI Net Products Sales Of $141M-143M Expected For 2023

- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited- LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89%

MIRM